

Meeting Report

27TH MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE-PREVENTABLE DISEASES IN THE WESTERN PACIFIC REGION



19–22 June 2018
Manila, Philippines



WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC

RS/2018/GE/98(PHL)

English only

MEETING REPORT

27TH MEETING OF THE TECHNICAL ADVISORY GROUP (TAG) ON
IMMUNIZATION AND VACCINE-PREVENTABLE DISEASES IN THE
WESTERN PACIFIC REGION

Convened by:

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC

Manila, Philippines
19–22 June 2018

Not for sale

Printed and distributed by:

World Health Organization
Regional Office for the Western Pacific
Manila, Philippines

October 2018

NOTE

The views expressed in this report are those of the participants of the 27th Meeting of the Technical Advisory Group (TAG) on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region and do not necessarily reflect the policies of the conveners.

This report has been prepared by the World Health Organization Regional Office for the Western Pacific for Member States in the Region and for those who participated in the 27th Meeting of the Technical Advisory Group (TAG) on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region in Manila, Philippines from 19 to 22 June 2018.

CONTENTS

SUMMARY	1
ABBREVIATIONS	2
1. INTRODUCTION	4
1.1 Meeting organization	4
1.2 Meeting objectives	4
2. PROCEEDINGS	4
2.1 Opening session	4
2.2 Global update	5
2.2.1 Global overview of WHO's roles in immunization	5
2.2.2 Global update on implementation of the GVAP	5
2.2.3 Regional update on progress towards the GVAP goals in the Western Pacific.....	6
2.3 Immunization systems strengthening (including progress towards GVAP strategic objectives)	6
2.3.1 Overview of immunization systems strengthening in the Western Pacific Region (1988–2000, 2003–2013 and 2014–2017).....	6
2.3.2 Update on regulatory systems strengthening and vaccine pharmacovigilance in the Western Pacific Region	7
2.3.3 Experiences and lessons learnt of a well-functioning national immunization technical advisory group (NITAG).....	7
2.3.4 Building advocacy capacity: vaccine hesitancy following dengue vaccine–related safety issues.....	7
2.3.5 Closing immunity gaps in rapidly urbanizing areas in the Western Pacific Region	8
2.3.6 New strategies to enable equitable immunization service delivery: boosting inactive poliovirus (IPV) coverage through periodic intensification of routine immunization.....	8
2.3.7 Securing vaccine supply: challenges and way forward	9
2.3.8 Operational research: improved delivery approaches for life-course immunization.....	9
2.3.9 Proposed actions for 2018–2020 to accelerate progress towards the GVAP strategic objectives	9
2.3.10 Proposed actions to strengthen immunization systems in the Western Pacific Region in 2021–2030.....	10
2.4 New vaccines introduction	10
2.4.1 Global overview and regional update.....	10

2.4.2	Experiences and lessons learnt of a lower middle-income country that has introduced three new vaccines since 2010 and will introduce two more in the next 1-2 years	10
2.4.3	Experiences and lessons learnt from the introduction of HPV in the Republic of Korea	11
2.4.4	Proposed actions for 2018–2020 and introduction of new vaccines into national immunization programmes in the Western Pacific Region in 2021–2030	11
2.5	Accelerated hepatitis B control	12
2.5.1	Global and regional overview	12
2.5.2	Hepatitis B birth dose improvement: lessons learnt from pilot projects in Viet Nam	12
2.5.3	EMTCT of HIV, hepatitis B and syphilis: an opportunity to further acceleration of hepatitis B control	12
2.5.4	Moving towards EMTCT of hepatitis B in China: field and modelling experiences and challenges	13
2.5.5	Proposed actions for 2018–2020 and accelerated hepatitis B control in the Western Pacific Region in 2021–2030.....	13
2.6	Sustaining polio-free status and implementation of the polio endgame strategies.....	14
2.6.1	Global update	14
2.6.2	Regional update.....	14
2.6.3	Update from the Regional Commission for the Certification of Poliomyelitis Eradication.....	14
2.6.4	Global supply of IPV and Strategic Advisory Group of Experts (SAGE) on immunization recommendations	15
2.6.5	Assessment of population immunity gap to poliovirus type 2	15
2.6.6	Update on polio laboratory network and environmental surveillance in the Western Pacific Region	16
2.6.7	Detection of vaccine-derived poliovirus (VDPV) type 2	16
2.6.8	Update on laboratory containment in the Western Pacific Region.....	16
2.6.9	Update on global polio eradication certification process	17
2.6.10	Proposed actions for sustaining polio-essential functions in 2018–2020 and polio programme in the Western Pacific Region in 2021–2030	17
2.7	Maternal and neonatal tetanus (MNT) elimination	18
2.7.1	Achieving MNT elimination in the Philippines	18
2.7.2	Regional overview and draft implementation guide for sustaining MNT elimination.....	18
2.8	Measles and rubella elimination.....	18
2.8.1	Global and regional overview	18
2.8.2	Report from Regional Verification Commission	19
2.8.3	Final regional strategy and plan of action for measles and rubella elimination	20

2.8.4	Developing a national plan of action for measles and rubella elimination in the Lao People's Democratic Republic.....	20
2.8.5	Draft operational guidelines for congenital rubella syndrome (CRS) surveillance.....	20
2.8.6	Sustaining elimination in the face of repeated measles importation	21
2.8.7	Measuring population immunity: results of a nationwide representative serological survey.....	21
2.8.8	Proposed actions for 2018–2020 and measles and rubella elimination in the Western Pacific Region in 2021–2030.....	21
2.9	Accelerated Japanese encephalitis control	22
2.9.1	Regional overview	22
2.9.2	Japanese encephalitis control in China.....	22
2.9.3	Draft regional guide for developing a national plan of action for accelerated JE control	23
2.10	Diphtheria outbreak.....	23
2.10.1	Findings on gap analysis on diphtheria diagnostic capacity for laboratories in the Western Pacific Region	23
2.10.2	Introducing diphtheria toxoid booster doses in routine immunization	23
2.10.3	Regional overview and draft regional field guide for preparedness and response to diphtheria outbreak in the Western Pacific Region	24
2.11	Surveillance, laboratory network and data management for vaccine-preventable disease (VPD) control and elimination	24
2.11.1	Introduction of new global guidelines on VPD surveillance.....	24
2.11.2	Proposed actions for 2018–2020 to further improve surveillance of VPD in the Western Pacific Region	25
2.11.3	Proposed actions for 2018–2020 to further improve surveillance systems to support introduction of new vaccines in the Western Pacific Region.....	25
2.11.4	Proposed actions for 2018–2020 to further improve VPD laboratory networks in the Western Pacific Region	25
2.12	Synergy with other areas and programmes	26
2.12.1	Roles of EPI in Sustainable Development Goals (SDGs) and universal health coverage / working for health system strengthening	26
2.12.2	Roles of EPI in International Health Regulations/working with WHO Health Emergencies Programme	26
2.13	Planning for the next decade	27
2.13.1	TAG report on progress of regional framework for implementation of the GVAP in the Western Pacific Region	27

2.13.2 Process of development of new global immunization strategy 2021–2030	27
2.13.3 Development of regional vision and strategy for VPDs and immunization 2021–2030	27
2.14 Partners' presentations	28
3. CONCLUSIONS AND RECOMMENDATIONS	30
3.1 Conclusions	30
3.2 Recommendations.....	39

Annex 1. List of participants

Annex 2. Meeting programme

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25724

